^
Association details:
| Biomarker: | Chr del(17p) |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/03/2020
Excerpt:
Nivolumab and pembrolizumab ± ibrutinib are included as options with a category 2B recommendation for patients unable to receive chemoimmunotherapy, patients with del (17p) or TP53 mutation, or those with chemoimmunotherapy-refractory disease.
